Our previous study showed that VC pretreatment might be a new treatment method of NAFLD/NASH through attenuate hepatocyte stress induced by TNFα via activation of the FGF21/FGFR2/adiponectin pathway (24). This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.